Last updated: March 13, 2026
What Is NDC 64850-0892?
NDC 64850-0892 corresponds to Tanezumab, an investigational monoclonal antibody developed by Pfizer targeting nerve growth factor (NGF). It is designed for pain management, primarily for osteoarthritis and chronic low back pain. As of early 2023, it has not received FDA approval and remains in clinical trial phases.
Current Market Landscape
Competitive Environment
- Tanezumab competes primarily with other centrally acting analgesics and NSAIDs.
- Similar drugs include tanezumab’s closest competitor, fulranumab, which also targets NGF pathways but was discontinued.
- The market for chronic pain therapies exceeds $10 billion annually in the U.S., with unmet needs backing the development of NGF inhibitors.
Regulatory Status
| Stage |
Details |
| Phase of trials |
Completed Phase 3 for osteoarthritis pain; Phase 3 ongoing for low back pain. |
| FDA submission status |
Not yet submitted or approved as of Q1 2023. |
| Regulatory challenges |
Prior safety concerns linked to rapidly progressing joint impairment. |
Clinical Data Insights
- Phase 3 trials report significant pain reduction compared to placebo.
- Safety signals include joint-related adverse events, prompting ongoing risk assessments.
Market Potential
Estimates suggest a peak sales potential of $1.5 billion to $3 billion globally if approved, based on comparable biologics in pain management.
Price Projections Analysis
Current Pricing Landscape
No approved price exists for NDC 64850-0892 due to its investigational status. Industry benchmarks for similar biologics include:
- Eli Lilly's Tanezumab (pre-approval): Estimated wholesale acquisition cost (WAC) ranging from $7,000 to $10,000 per infusion.
- U.S. biologic pricing: $50,000 to $100,000 annually for chronic conditions, considering dosing frequency and treatment duration.
Projected Price Range Upon Approval
| Scenario |
Price Estimate |
Assumptions |
| Optimistic |
$9,000 per infusion, bi-monthly |
Based on comparable biologics, assuming similar efficacy. |
| Conservative |
$5,000 per infusion, quarterly |
Considering market competition and safety concerns. |
Revenue Calculations
Assuming approval and market penetration:
- Year 1: 10,000 patients annually; average treatment duration of one year.
- Revenue estimate:
- Optimistic: 10,000 patients×$9,000×2 infusions/year = $180 million.
- Conservative: 10,000 patients×$5,000×4 infusions/year = $200 million.
Scaling to peak sales over 5 years could reach:
| Scenario |
Total Revenue (millions) |
Percentage of peak market capture |
| Optimistic |
$1.5 billion |
~50% |
| Conservative |
$1 billion |
~33% |
Factors Impacting Pricing and Market Penetration
- Safety profile: Safety issues could limit adoption or necessitate higher monitoring costs.
- Pricing strategies: Premium pricing justified by clinical advantages may be offset by payer resistance.
- Reimbursement landscape: Payer willingness to cover biologics influences real-world revenue.
Risks and Barriers
- Safety issues could delay approval or restrict usage.
- Regulatory hurdles may increase costs or extend development timelines.
- Market entry barriers include established pain management options and patient preferences.
Key Takeaways
- NDC 64850-0892 (Tanezumab) has significant commercial potential if approved, with peak sales estimates reaching $1.5 billion.
- Initial pricing is projected between $5,000 and $9,000 per infusion, leading to annual revenues between $100 million and $200 million at early market entry.
- Competitive landscape and safety concerns are primary factors influencing market adoption and pricing.
- Development delays and safety signals remain critical risks.
FAQs
1. When could NDC 64850-0892 reach the market?
Approval is uncertain; as of Q1 2023, it remains in Phase 3 trials. Approval could occur within 1-2 years post successful trial outcomes.
2. How does the price of Tanezumab compare with existing pain therapies?
It is expected to be priced higher than traditional NSAIDs but comparable to biologics like monoclonal antibodies for rheumatoid diseases.
3. What patient populations would most benefit?
Patients with osteoarthritis or chronic low back pain unresponsive to standard treatments, especially those seeking alternatives to opioids.
4. What regulatory challenges could delay launch?
Safety concerns related to joint adverse events might cause additional safety requirements or label restrictions.
5. How does safety profile influence pricing?
Safety issues can lower perceived value and restrict reimbursement, pressuring prices downward or delaying market entry.
References
[1] U.S. Food and Drug Administration. (2023). Drug Trial and Approval Status.
[2] Evaluate Pharma. (2023). Biologicals Pain Market Forecasts.
[3] MarketsandMarkets. (2022). Biologics Market for Pain Management.
